Vaccine Preventability of Meningococcal Clone, Greater Aachen Region, Germany
Johannes Elias , Leo M. Schouls, Ingrid van de Pol, Wendy C. Keijzers, Diana R. Martin, Anne Glennie, Philipp Oster, Matthias Frosch, Ulrich Vogel1, and Arie van der Ende1
Author affiliations: University of Wuerzburg, Wuerzburg, Germany (J. Elias, M. Frosch, U. Vogel); National Institute for Public Health and Environment (RIVN), Bilthoven, the Netherlands (L.M. Schouls, I. van de Pol); Academic Medical Center, Amsterdam, the Netherlands (W.C. Keijzers, A. van der Ende); Institute of Environmental Science and Research, Porirua, New Zealand (D.R. Martin, A. Glennie); Novartis Vaccines, Siena, Italy (P. Oster)
Figure 1. Distribution of clonal complex 41/44 Neisseria meningitidis strains in Germany and the Netherlands during 2001–2006 with positively associated multiple-locus variable-number tandem repeat analysis (MLVA) and multilocus sequence types (MLST). A) Distribution of MLVA type (MT) 19/MLST (ST) 42 strains (red triangles). Full green circles represent non–MT19/ST42 strains. Black rectangle delineates the area magnified in panel B. B) Area encompassing Limburg (orange shading) and Greater Aachen (blue shading). C–E) Spatial distribution of other overrepresented MT/ST variants: MT27/ST40 (blue triangles); MT30/ST40 (orange triangles); MT78/ST1374 (purple triangles).
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.